Cortinovis Diego Luigi, Leonetti Alessandro, Morabito Alessandro, Sala Luca, Tiseo Marcello
Division of Medical Oncology, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy.
School of Medicine and Surgery, University of Milano Bicocca, 20126 Milan, Italy.
Cancers (Basel). 2024 Jul 22;16(14):2610. doi: 10.3390/cancers16142610.
Targeted therapies changed the treatment of advanced oncogene-addicted non-small cell lung cancer and could also improve outcomes in resectable disease.
The ALINA trial evaluated the clinical benefit of adjuvant alectinib compared with standard chemotherapy and met the primary endpoint with a significant increase in disease-free survival at 2 years among anaplastic lymphoma kinase positive patients with stage IB-IIIA disease; two phase II trials (ALNEO and NAUTIKA1) are currently evaluating perioperative treatment with alectinib, and the results of the case reports published to date are encouraging.
In resectable anaplastic lymphoma kinase-positive lung cancer, adjuvant alectinib represents the new standard of care and could soon be used in perioperative treatment.
靶向治疗改变了晚期致癌基因依赖性非小细胞肺癌的治疗方式，也能改善可切除疾病的治疗效果。
ALINA试验评估了阿来替尼辅助治疗与标准化疗相比的临床获益，在IB-IIIA期间变性淋巴瘤激酶阳性患者中达到了主要终点，2年无病生存率显著提高；两项II期试验（ALNEO和NAUTIKA1）目前正在评估阿来替尼的围手术期治疗，迄今发表的病例报告结果令人鼓舞。
在可切除的间变性淋巴瘤激酶阳性肺癌中，阿来替尼辅助治疗代表了新的治疗标准，可能很快用于围手术期治疗。
